Salomao V.: Innovation in Hemophilia A Is Also About How Patients Receive Their Treatment
Salomao V., Partner in the Biopharmaceutical Industry, shared a post on LinkedIn:
“It’s encouraging to see more treatment options becoming available for people living with rare diseases. Novo Nordisk has received European Commission approval for Frehemgo, a new treatment for people with hemophilia A.
One thing that caught my attention is the flexibility in dosing.
Patients can receive it as a simple injection under the skin, with options ranging from once a week to once a month.
For people who need ongoing preventive treatment, having more flexible options could make everyday life a little easier.
I think developments like this show why innovation in biopharmaceuticals matters.
It’s not just about developing new drugs, but also finding ways to make treatment more manageable for patients.”
Stay updated with Hemostasis Today.
-
Nov 19, 2026, 22:16Jonathan Penm: Perioperative Anticoagulation Management and Antithrombotic Stewardship Across 31 Countries
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing
-
Nov 19, 2026, 14:19Long-Read Sequencing Is Closing Diagnostic Gaps in Inherited Bleeding Disorders
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI